Accelerating Science: How to cure the incurable with cell and gene therapy

Cutting-edge genotyping chemistries from high-throughput to point-of-care oncology testing
Available on demand

Molecular testing for oncology plays a crucial role in cancer diagnosis, prognosis, treatment selection, and monitoring. Traditionally reliant on tissue biopsies, advancements in technology now allow molecular testing using less invasive bodily fluids, expanding accessibility. Meridian Bioscience, a leader in qPCR and isothermal chemistries, offers innovative reagents for commercial assays designed to detect mutations, including single nucleotide polymorphisms (SNPs).

In this webinar, Dr. William Ferreria, R&D Team leader, and Dr. Steve Hawkins, Molecular Product Marketing Manager both from Meridian Bioscience, will provide an insight into the latest range of Lyo-Ready™ Genotyping Direct qPCR Master mixes, which offer significant advantages including a simplified workflow, superior cluster resolution and allelic discrimination, and compatibility with lyophilization.

Key learning objectives

  • Explore the latest technology developments for faster genotyping testing from high-throughput to point-of-care
  • Discover how SNPs can be detected directly from blood, plasma, urine, stool, or FFPE tissue (down to 1 copy/reaction) using Lyo-Ready™ Genotyping Direct qPCR Master mixes, eliminating the need for nucleic acid extraction
  • Understand how SNPs can aid in predicting cancer risk and response to certain drugs

Who should attend?

  • IVD companies: procurement, and R&D: oncology and precision medicine

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Meridian Bioscience Inc.